The aim of this study was to evaluate the pharmacokinetics and penetration of moxifloxacin (MXF) in patients with various types of pleural effusion. Twelve patients with empyema/parapneumonic effusion (PPE) and 12 patients with malignant pleural effusion were enrolled in the study. A single-dose pharmacokinetic study was performed after intravenous administration of 400 mg MXF. Serial plasma (PL) and pleural fluid (PF) samples were collected during a 24-h time interval after drug administration. The MXF concentration in PL and PF was determined by high-performance liquid chromatography, and main pharmacokinetic parameters were estimated. Penetration of MXF in PF was determined by the ratio of the area under the concentration-time curve from time zero to 24 h (AUC 24 ) in PF (AUC 24PF ) to the AUC 24 in PL. No statistically significant differences in the pharmacokinetics in PL were observed between the two groups, despite the large interindividual variability in the volume of distribution, clearance, and elimination half-life. The maximum concentration in PF (Cmax PF ) in patients with empyema/PPE was 2.23 ؎ 1.31 mg/liter, and it was detected 7.50 ؎ 2.39 h after the initiation of the infusion. In patients with malignant effusion, Cmax PF was 2.96 ؎ 1.45 mg/liter, but it was observed significantly earlier, at 3.58 ؎ 1.38 h (P < 0.001). Both groups revealed similar values of AUC 24PF (31.83 ؎ 23.52 versus 32.81 ؎ 12.66 mg · h/liter). Penetration of MXF into PF was similarly good in both patient groups (1.11 ؎ 0.74 versus 1.17 ؎ 0.39). Despite similar plasma pharmacokinetics, patients with empyema/parapneumonic effusion showed a significant delay in achievement of PF maximum MXF levels compared to those with malignant effusion. However, in both groups, the degree of MXF PF penetration and the on-site drug exposure, expressed by AUC 24PF , did not differ according to the type of pleural effusion.
T he development of a pleural effusion is a common complication of pneumonia, occurring in up to 57% of cases. The majority of these effusions are clear, sterile exudates that frequently resolve with antimicrobial treatment and do not require drainage. In some cases, this initial effusion may progress to a complicated parapneumonic effusion (PPE), which is characterized by fibrin deposition and fluid infection. These effusions cannot resolve without drainage and usually require placement of a chest tube. Persistent pleural infection may result in the accumulation of pus in the pleural space, which is called "empyema" (1) .
All patients with parapneumonic effusion or empyema should initially be treated with intravenous antibiotics. The initial selection of the agent and dose is usually based on whether the patient has community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP) and depends on the severity of the patient's clinical condition (2) . Respiratory fluoroquinolones, such as moxifloxacin (MXF) or levofloxacin, are recommended as initial empirical antibiotic therapy both for hospitalized patients with severe and nonsevere CAP (3) and for those with HAP or ventilator-associated pneumonia without known risk factors for multidrug-resistant pathogens and early onset (4) .
MXF is widely used in the treatment of community-acquired pneumonia and pleural effusion due to its broad antimicrobial activity against Gram-positive and Gram-negative bacteria, including anaerobes (1) . Although there are several studies (5) (6) (7) (8) (9) about ciprofloxacin (CIP) penetration in human pleural fluid (PF), data on MXF are scarce and are based on experimental pleural empyema in rabbits (10, 11) . On the basis of these data, MXF penetrates well into infected rabbit pleural fluid. However, limitations, such as the different route and time of MXF administration, the difference in visceral pleura thickness between human and rabbit, and the turpentine-induced empyema, render the extrapolation of these results to human patients uncertain. To the best of our knowledge, despite its widespread use during the last 15 years, there are no studies investigating MXF penetration either in human empyema or in effusions due to other etiologies.
The aim of the present study was to determine the pharmacokinetics (PK) of MXF in plasma (PL) and human pleural fluid and to evaluate under actual clinical conditions its penetration into human exudative pleural fluid effusions of different etiologies, namely, empyemic/parapneumonic and malignant effusions.
MATERIALS AND METHODS
Study design. The study was designed as a prospective, open-label study and took place in the Pulmonary Department of the G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, from October 2012 to June 2013. The research was conducted in accordance with the Declaration of Helsinki as well as national and institutional standards. The study protocol was approved by the institutional review board of G. Papanikolaou Hospital (reference no. 12/25-10-2012), and written informed consent was obtained from all study participants.
Patient population. Patients were eligible for enrollment in the study if they were admitted to the Pulmonary Department for empyema/para-pneumonic effusion or exudative malignant pleural effusion and had in place a chest tube for continuous drainage. The documentation of the pleural effusion's etiology was based on clinical manifestations, imaging studies, and pleural fluid biochemical analysis, microbiology, and cytology (12) . Differentiation of transudates from exudates was performed according to the criteria of Light et al. (13) .
A complete medical history and laboratory test results, including complete blood cell counts, erythrocyte sedimentation rate, serum glucose and electrolyte levels, liver function test results, total protein and albumin concentrations, serum creatinine levels, and results of urine analyses, were recorded prior to the commencement of the protocol. Pleural fluid specimens were examined for glucose, pH, lactate dehydrogenase (LDH) and protein levels, and total white blood cell count and differential. Samples of pleural fluid underwent Gram's staining, microbiology, and cytology studies upon clinical indication. Exclusion criteria were as follows: a history of allergy to fluoroquinolones, a prolonged Q-T interval, renal insufficiency (defined as a creatinine clearance [CL CR ] of 30 ml/min or less, as calculated by the Cockcroft-Gault equation [14] ), hepatic impairment (defined as a Child-Pugh score of B or C), a history of convulsions, and concomitant therapy with cytostatic agents.
MXF was prescribed empirically to the patients suffering from empyema or parapneumonic pleural effusion by their treating physician. MXF was given intravenously to these patients at a dosage of 400 mg every 24 h by infusion over 1 h via a peripheral venous line, and the study was conducted on the first day of treatment. Patients with malignant pleural effusion were administered a single intravenous dose of 400 mg MXF only for study purposes.
Specimen collection. Blood samples were obtained via a separate peripheral venous catheter just prior to the MXF administration (time zero) and at the following time points postdosing: 1 h (at the end of the infusion), 2 h, 3 h, 4 h, 6 h, 9 h, 12 h, and 24 h. Pleural fluid samples were obtained through a chest tube at the same time points. Plasma was separated from whole blood by centrifugation. All plasma and pleural fluid samples were stored at Ϫ20°C until analysis.
Moxifloxacin HPLC assay. MXF (Bayer AG, Leverkusen, Germany) concentrations in plasma and pleural fluid were determined using highperformance liquid chromatography (HPLC) with fluorescence detection according to the method previously described by Liang et al., with modifications (15) .
Analytical separation was performed via a Nucleosil 100C 18 , 250-by 4.6-mm, 5-m column (M-Z Analysentechnic, Mainz, Germany) protected by a guard column (20 by 4.6 mm; 5 m) of the same composition. The detector was set at an excitation wavelength of 293 nm and at an emission wavelength of 500 nm. The mobile phase consisted of 10 mM sodium dodecyl sulfate, 25 mM citric acid, 10 mM tetrabutylammonium hydrogen sulfate with 43% (vol/vol) acetonitrile at pH 3.5 adjusted with NaOH (1 N). CIP (Elpen Pharmaceuticals, Athens, Greece) was used as the internal standard. The isocratic flow rate was 1 ml/min, the column temperature was set at 37°C, the total run time was 7 min, and the retention times of CIP and MXF were 4.4 and 6.1 min, respectively.
Coefficients of determination (r) (2) for MXF and CIP over the standard curve concentrations of 0.05 to 10 mg/liter for plasma and pleural fluid were 0.999 for the entire study. Intraday and interday coefficients of variation were Ͻ5%. The rates of recovery of MXF and CIP in plasma and pleural fluid were greater than 100% and 99%, respectively.
Sample preparation and extraction procedure. Fifty microliters of an internal standard solution of 20 mg/liter and 500 l of acetonitrile were added to 250 l of plasma or pleural fluid, and the mixture was then vortexed for 30 s and centrifuged at 3,600 rpm for 10 min (Zentrifugen Micro 20; Hettich, Germany). The clear supernatant was then injected into the column via an autosampler and a 20-l loop.
Pharmacokinetic analysis. PL and PF MXF concentrations were plotted against time, and the pharmacokinetic parameters were estimated by compartmental analysis using the WinNonlin software program (version 3.0; Pharsight Corporation, Mountain View, CA). A two-compartment model with first-order elimination and no lag time was used, and the goodness of fit of the model was determined by using the Akaike and Schwartz criteria, as well as the correlation between the observed and the calculated concentrations. The peak (maximum) concentration in plasma (Cmax PL ) and the trough (minimum) concentration in plasma (Ctrough PL ) were observed at 24 h postdosing. The peak (maximum) concentration in pleural fluid (Cmax PF ) and the time to reach Cmax PF (Tmax PF ) were obtained observationally from individual concentrationtime data. All concentrations in both matrices were total drug concentrations. The area under the concentration-time curve from time zero to 24 h (AUC 24 ) was determined by the trapezoidal rule. The penetration ratio for each patient was obtained by dividing the AUC 24 for pleural fluid (AUC 24PF ) by the AUC 24 for plasma (AUC 24PL ). Calculation of the volume of distribution (V), total body clearance (CL), and elimination halflife (t 1/2 ) was performed by a compartmental method, as described above.
Statistical analysis. All data are expressed as means Ϯ standard deviations unless otherwise noted. Biostatistical analysis was performed using SPSS for Windows, release 17.0.1 (standard version; SPSS Inc.). The normality of the distribution was assessed by the Shapiro-Wilk test. Pharmacokinetic parameters between empyemic/parapneumonic and malignant effusions were compared by an independent samples t test if the data were Patients with malignant pleural effusion (n ϭ 12) 
RESULTS
Twenty-four patients (19 males and 5 females) were included in the study. Twelve of these patients were admitted to the hospital due to complicated parapneumonic effusion (PPE) or empyema (group A), and the rest suffered from malignant pleural effusion (group B). Their demographics and pleural fluid characteristics are shown in Tables 1 and 2 , respectively. The pharmacokinetic parameters of MXF in plasma for both patient groups are summarized in Table 3 . The mean peak concentrations in plasma were 4.64 Ϯ 0.68 mg/liter for group A and 4.28 Ϯ 0.69 mg/liter for group B, respectively, and were achieved by the end of drug infusion. The observed mean concentrations in plasma at 24 h (Ctrough PL ) were 0.37 Ϯ 0.13 mg/liter for group A and 0.39 Ϯ 0.07 mg/liter for group B. A large variability in the pharmacokinetic data was observed for both groups, especially in V, which ranged from 82.66 to 310.95 liters, although their mean values were similar (165.12 liters for group A versus 155.22 liters for group B). Similarly, CL ranged from 6.82 to 19.10 liters/h, and t 1/2 was as short as 3.84 h and as long as 36.20 h. In both groups, a similar AUC 24PL was observed (28.39 Ϯ 5.47 mg · h/liter for group A versus 28.06 Ϯ 4.37 mg · h/liter for group B).
Regarding the pleural fluid, the mean Cmax PF in patients with empyema/PPE was 2.23 Ϯ 1.31 mg/liter, and it was detected 7.50 Ϯ 2.39 h after the initiation of the infusion. In patients with malignant effusion, the mean Cmax PF was 2.96 Ϯ 1.45 mg/liter, and it was observed significantly earlier at 3.58 Ϯ 1.38 h after the start of the infusion (P Ͻ 0.001). Both groups revealed a similar mean AUC 24PF (31.83 Ϯ 23.52 mg · h/liter for group A versus 32.81 Ϯ 12.66 mg · h/liter for group B), but patients with empyema/PPE showed a remarkable interindividual variability (AUC 24PF range, 51 to 96.11 mg · h/liter). The penetration of MXF into pleural fluid was similarly good in patients from both groups (1.11 Ϯ 0.74 for group A versus 1.17 Ϯ 0.39 for group B). The mean Ctrough PF was found to be 0.99 Ϯ 0.84 for group A and 0.73 Ϯ 0.46 mg/liter for group B, with empyemic patients showing a slightly higher-but not statistically significant-trough concentration of moxifloxacin at the end of the 24-h interval. The equilibration of the MXF concentration between plasma and pleural fluid occurred at 5 h in patients with empyema/parapneumonic effusion, whereas it occurred at 3 h in those with malignant effusion. The pharmacokinetic parameters of MXF in pleural fluid for both patients groups are summarized in Table 4 , while Fig. 1A and B represent the concentration-time curves of MXF in the plasma and pleural fluid of the two groups.
In order to overcome the age difference between the two groups, we assessed the PF pharmacokinetic data in two subgroups of the 10 older patients with empyema/PPE (mean age, 61.9 years) and compared them to the data for the eight younger patients with malignant effusion (mean age, 63.8 years 
DISCUSSION
Antibiotic penetration into the site of infection is critical in order to achieve a favorable clinical outcome. The success of an antimicrobial agent in the treatment of pleural space infection depends on the achievement of sufficient drug concentrations in the pleura and, more specifically, in pleural fluid (16, 17) . For the first time in the literature, results from the present study indicate that MXF penetrates sufficiently into pleural fluid in patients with empyema and those with malignant effusion, though penetration is significantly slower in the empyemic patients.
In general, it is believed that antibiotic levels in pleural fluid are similar to those in serum, but most studies in humans involved patients with diseases other than empyema (18). Teixeira et al. have suggested that pleural fluid antibiotic levels are lower than serum antibiotic levels in patients with empyema, due to the decreased permeability of the thickened pleura and the more acidic local environment (19) . On the contrary, under circumstances of acute infection, which involves inflammation, vasodilation, edema, and increased membrane permeability, the penetration of antimicrobial agents may be increased (20) .
Therefore, it is important to evaluate the penetration of antibiotics into the pleural space, and careful consideration should be given to the underlying pathophysiology and the different mechanisms of fluid formation. In empyema, during the exudative stage, pleural fluid accumulates in the pleural space secondary to inflammation and the increased permeability of the visceral pleura. As the infection progresses, the bacterial invasion of the pleural space, the deposition of fibrin on pleural membranes, and the formation of septations lead to a thick, nonelastic pleural peel (21) . Regarding malignant effusions, which are predominantly exudates (22) , the main mechanisms of fluid production include impaired drainage of the pleural space due to obstruction of blood vessels and lymphatics of the lung and pleura and increased formation of pleural fluid (23) .
Hence, it could be assumed that the penetration of antimicrobial agents into pleural effusions of a different etiology could vary according to the underlying pathophysiology. Indeed, in a rabbit model of empyema, penetration of antibiotics varied significantly (19) . On the other hand, a previous study concluded that there is very little difference between chemically diverse antimicrobial agents in their degree of pleural penetration (18) . Notably, none of these studies included fluoroquinolones, a class of antimicrobials able to achieve a large volume of distribution and extensive tissue penetration (24) . There are indications that the antimicrobial activity of compounds like MXF, which is devoid of a piperazinyl ring at position 7, is not affected by acidic conditions (25) . Therefore, it could be expected that newer fluoroquinolones, and specifically MXF, would be an attractive treatment option for infected or contaminated pleural effusions. The present data are in favor of this hypothesis.
Our results show that the interindividual variability of MXF's pharmacokinetic parameters is considerable. This could be explained by the fact that all subjects were seriously ill, and therefore, pharmacokinetic parameters were subjected to a number of modifying factors, such as cardiac performance, the adequacy of tissue perfusion, coadministration of drugs, and competition for the same metabolic pathways (26) . Moreover, it is known that the genetic variability of the metabolic pathways represents a major modifying factor (27) . It is evident that the coexistence of more than one modifying factor in a given patient makes determination of the individual contribution practically impossible. Nevertheless, MXF revealed similar pharmacokinetic characteristics (e.g., C max , C trough , AUC 24 , and AUC 24PF /AUC 24PL ) in both groups of patients, confirming its excellent ability to penetrate into tissue compartments independently of the degree of inflammation or pH reduction.
The main finding in our study is the statistically significant prolongation of Tmax PF in the group of patients with empyema/ parapneumonic effusion and the slightly lower Cmax PF . Correspondingly, the same group of patients tended to achieve higher trough moxifloxacin levels in pleural fluid, although the difference did not reach statistical significance. It could be assumed that fibrin deposition on pleural surfaces, along with a degree of thickening, raises a barrier to prompt penetration into the pleural space. Notwithstanding, MXF was able to achieve AUCs in pleural fluid equal to or higher than those obtained in plasma in both groups of patients, indicating that microbial exposure to the drug's antimicrobial action is not compromised by tissue factors or the degree of the inflammatory process. However, patients with empyema/PPE showed a remarkable variation in AUC 24PF , indicating that in some patients, therapeutic drug monitoring and treatment individualization may be needed.
Time (hours)
The main limitation of the present study was the age difference between the two groups. Although the possibility that this difference may interfere with MXF penetration into PF cannot be excluded, we do not believe that this is the case, for two reasons. First, both groups had similar plasma pharmacokinetic profiles, despite the age difference. Second, patients of similar ages from both groups maintained the same PF pharmacokinetic characteristics as the original groups. Therefore, it is reasonable to assume that the delay in Tmax PF in the case of empyema/parapneumonic effusion does not result from age-dependent differences in the MXF tissue distribution.
The results of the present study support the wide empirical use of MXF in the treatment of parapneumonic effusion and empyema, providing evidence for the first time under actual clinical conditions that MXF sufficiently penetrates into the pleural space and exhibits a favorable pharmacokinetic profile regardless of pleural fluid origin. The delay in the achievement of the maximum pleural fluid MXF concentration observed in patients with PPE/ empyema may trigger further studies on the penetration of different antibiotics into the pleural space.
